Trial Profile
A phase II trial of thalidomide and capecitabine in metastatic renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2010
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Thalidomide (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 12 May 2009 Additional lead trial investigator (Srinivas S) identified as reported by ClinicalTrials.gov.
- 14 Jun 2007 Status changed from in progress to completed
- 27 Nov 2005 New trial record.